309 results
Page 6 of 16
8-K
EX-99.1
j9xxc
3 Mar 14
BioTime Provides Financing and Product Development Update
12:00am
8-K
EX-99.1
r8q 6bpk3sfg1p9hok9u
27 Jan 14
BioTime, Inc. Subsidiary OncoCyte Corporation Initiates Clinical Development of Bladder Cancer Diagnostics in the United States and China
12:00am
8-K
EX-99.1
9e88q0guc
17 Jan 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
mgyv9 83z4im2yv3jd
13 Jan 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
8wjznllkikvvcjm
2 Jan 14
Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Leases Facilities for Expanded Product Development and Manufacturing
12:00am
8-K
EX-99.1
3z18lve
23 Dec 13
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel’s Office of the Chief Scientist
12:00am
8-K
EX-99.1
n17k5mw2ban mh
6 Dec 13
LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.11
12:00am
8-K
EX-99.1
xjys4 i03f9hkozzcsbs
4 Dec 13
BioTime’s CEO, Dr. Michael West to Moderate Session on Mapping the Cellular Basis of Life at the 2013 World Stem Cell Summit
12:00am
8-K
EX-99.1
dkhii0921j0m
2 Dec 13
Asterias Biotherapeutics, Inc. Files Registration Statement for Underwritten Public Offering
12:00am
8-K
EX-99.1
epvoj1utb5zyoo
25 Nov 13
BioTime CEO Dr. Michael West to Present at 11th Annual Commercial Translation of Regenerative Medicine Conference
12:00am
8-K
EX-99.1
orl9 ndhp
28 Oct 13
BioTime Reports Interim Results on Renevia™ Clinical Safety Trial
12:00am
8-K
EX-99.1
3n9bffv5 zbbtcu
28 Oct 13
Regulation FD Disclosure
12:00am
8-K
EX-99.1
bfq65 cgclzrlr
28 Oct 13
BioTime Organizes New ESI BIO Division to Develop, Manufacture and Market the Company’s Cell-Based Research Products
12:00am
8-K
EX-99.1
nma3chojsqo96c3fw
4 Oct 13
BioTime Announces Additional Products in Development Based on HyStem® Technology
12:00am
8-K
EX-99.1
k6mvk 61ay8g
1 Oct 13
Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Acquires Geron’s Embryonic Stem Cell Assets
12:00am
8-K
EX-99.1
t2c7hnedob6efekqco
19 Sep 13
BioTime Signs Exclusive Agreement with Jade Therapeutics for Ophthalmic Drug Delivery Applications of HyStem® Technology
12:00am
8-K
EX-99.1
9sc8jtedc8
28 Aug 13
BioTime Receives Approval to Begin Human Clinical Trials of Renevia
12:00am